Table 1. Baseline characteristics.
| Variable | Mean±SD or N(%) |
|---|---|
| Age at diagnosis | |
| <40 | 249(12.89) |
| 40-49 | 635(32.88) |
| 50-59 | 598(30.97) |
| Over60 | 449(23.25) |
| Pathologic stage | |
| 1 | 596(30.86) |
| 2 | 840(43.5) |
| 3 | 430(22.27) |
| 4 | 65(3.37) |
| ER+ | 1249(65.09) |
| PR+ | 1000(52.14) |
| ER+ or PR+ | 1334(69.52) |
| HER2 | 614(35.66) |
| Cell Differentiation | |
| well | 200(10.36) |
| moderate | 951(49.25) |
| poor | 780(40.39) |
| Hb at diagnosis | 12.8±1.4 |
| Surgery | 1928(99.9) |
| Chemotherapy | 1351(70.0) |
| Radiotherapy | 1064(55.13) |
| Parity Hx | 1640(88.60) |
Abbreviations: ER+, estrogen receptor positive. PR+, progesterone receptor positive. ER+ or PR+, estrogen or progesterone receptor positive. HER2, human epidermal growth factor receptor 2 positive.Hb, hemoglobin. Hx, history.